Dyadic (DYAI) Revenue & Revenue Breakdown
Dyadic Revenue Highlights
Latest Revenue (Y)
$2.90M
Latest Revenue (Q)
$1.96M
Dyadic Revenue by Period
Dyadic Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $2.90M | -1.07% |
| 2022-12-31 | $2.93M | 21.90% |
| 2021-12-31 | $2.40M | 50.06% |
| 2020-12-31 | $1.60M | -4.71% |
| 2019-12-31 | $1.68M | 29.77% |
| 2018-12-31 | $1.30M | 70.81% |
| 2017-12-31 | $758.42K | 27.92% |
| 2016-12-31 | $592.89K | 87.79% |
| 2015-12-31 | $315.71K | -97.48% |
| 2014-12-31 | $12.52M | -26.91% |
| 2013-12-31 | $17.13M | 11.38% |
| 2006-12-31 | $15.38M | -3.14% |
| 2005-12-31 | $15.88M | -5.12% |
| 2004-12-31 | $16.74M | 7823.84% |
| 2003-12-31 | $211.27K | - |
Dyadic generated $2.90M in revenue during NA 2023, up -1.07% compared to the previous quarter, and up 223.77% compared to the same period a year ago.
Dyadic Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $1.96M | 407.26% |
| 2024-06-30 | $385.90K | 15.32% |
| 2024-03-31 | $334.62K | -51.26% |
| 2023-12-31 | $686.53K | 72.90% |
| 2023-09-30 | $397.06K | -52.57% |
| 2023-06-30 | $837.16K | -14.41% |
| 2023-03-31 | $978.05K | 31.51% |
| 2022-12-31 | $743.73K | -15.45% |
| 2022-09-30 | $879.60K | 33.57% |
| 2022-06-30 | $658.55K | 1.56% |
| 2022-03-31 | $648.43K | 106.97% |
| 2021-12-31 | $313.29K | -54.79% |
| 2021-09-30 | $692.93K | -26.06% |
| 2021-06-30 | $937.09K | 103.49% |
| 2021-03-31 | $460.52K | 33.13% |
| 2020-12-31 | $345.92K | -16.92% |
| 2020-09-30 | $416.36K | -20.58% |
| 2020-06-30 | $524.27K | 66.24% |
| 2020-03-31 | $315.37K | -27.19% |
| 2019-12-31 | $433.17K | -4.69% |
| 2019-09-30 | $454.51K | 16.28% |
| 2019-06-30 | $390.87K | -2.89% |
| 2019-03-31 | $402.53K | -41.40% |
| 2018-12-31 | $686.88K | 161.21% |
| 2018-09-30 | $262.96K | 63.04% |
| 2018-06-30 | $161.29K | -12.50% |
| 2018-03-31 | $184.33K | 17.41% |
| 2017-12-31 | $157.00K | -42.38% |
| 2017-09-30 | $272.49K | 31.38% |
| 2017-06-30 | $207.40K | 70.66% |
| 2017-03-31 | $121.53K | -75.25% |
| 2016-12-31 | $491.05K | 100.00% |
| 2016-09-30 | - | -100.00% |
| 2016-06-30 | $14.95K | -82.80% |
| 2016-03-31 | $86.89K | 189.72% |
| 2015-12-31 | $29.99K | -85.95% |
| 2015-09-30 | $213.49K | 726.34% |
| 2015-06-30 | $25.84K | -32.28% |
| 2015-03-31 | $38.15K | -99.70% |
| 2014-12-31 | $12.53M | 100.00% |
| 2014-09-30 | - | -100.00% |
| 2014-03-31 | $2.99M | -27.40% |
| 2013-12-31 | $4.11M | 18.82% |
| 2013-09-30 | $3.46M | -51.13% |
| 2013-06-30 | $7.08M | 185.31% |
| 2013-03-31 | $2.48M | -1.51% |
| 2012-09-30 | $2.52M | -67.88% |
| 2012-06-30 | $7.85M | 211.00% |
| 2012-03-31 | $2.52M | -25.44% |
| 2006-12-31 | $3.38M | -19.53% |
| 2006-09-30 | $4.20M | 5.93% |
| 2006-06-30 | $3.97M | 3.76% |
| 2006-03-31 | $3.83M | -4.84% |
| 2005-12-31 | $4.02M | -2.89% |
| 2005-09-30 | $4.14M | 3.81% |
| 2005-06-30 | $3.99M | 6.79% |
| 2005-03-31 | $3.73M | -77.69% |
| 2004-12-31 | $16.74M | 100.00% |
| 2004-09-30 | - | -100.00% |
| 2004-06-30 | $29.87K | -36.37% |
| 2004-03-31 | $46.94K | -77.78% |
| 2003-12-31 | $211.27K | 100.00% |
| 2003-09-30 | - | -100.00% |
| 2003-06-30 | $40.83K | -14.61% |
| 2003-03-31 | $47.82K | - |
Dyadic generated $1.96M in revenue during Q3 2024, up 407.26% compared to the previous quarter, and up 233.83% compared to the same period a year ago.
Dyadic Revenue Breakdown
Dyadic Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 | Mar 24 |
|---|---|---|---|
| License | $1.43M | - | - |
| Research and Development | $532.50K | $385.90K | $334.62K |
Latest
Dyadic's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License (72.80%), and Research and Development (27.20%).
Dyadic Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HOWL | Werewolf Therapeutics | $19.94M | $1.14M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| DYAI | Dyadic | $2.90M | $1.96M |
| HCWB | HCW Biologics | $2.84M | $426.42K |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| FBRX | Forte Biosciences | - | - |
| CCCC | C4 Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| DMAC | DiaMedica Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| CELC | Celcuity | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| CSBR | Champions Oncology | - | $-14.06M |